Peringatan Keamanan

There is limited information regarding the acute toxicity and overdosage of talquetamab.

Talquetamab

DB16678

biotech approved investigational

Deskripsi

Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain.L47765 Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells. It works to recruit CD3-expressing T cells to GPRC5D-expressing multiple myeloma cells to induce T-cell–mediated cytotoxicity.A260890

The Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended conditional marketing authorization for talquetamab for the treatment of relapsed or refractory multiple myeloma on July 21, 2023.L47775 Talquetamab was fully approved by the EMA on August 22, 2023.L48822 On August 9, 2023, talquetamab was granted FDA accelerated approval.L47770

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean (CV%) terminal half-life was 8.4 (41%) days after the first treatment dose and 12.2 (49%) days at 16 weeks after the first treatment dose.[L47765]
Volume Distribusi The geometric mean (CV%) volume of distribution of talquetamab was 10.1 L (25%).[L47765]
Klirens (Clearance) Talquetamab clearance decreases over time, with a mean (CV%) maximal reduction from the first treatment dose to 16 weeks after the first treatment dose of 40% (56%). The geometric mean (CV%) clearance is 0.90 L/day (63%) at 16 weeks after the first treatment dose.[L47765]

Absorpsi

The Cmax and AUCtau of talquetamab after subcutaneous administration increased proportionally over a dose range of 0.005 to 0.8 mg/kg weekly (0.01 to 2 times the recommended 0.4 mg/kg weekly treatment dose) and 0.8 to 1.2 mg/kg every two weeks (1 to 1.5 times the recommended 0.8 mg/kg every two weeks treatment dose). Ninety percent of steady-state exposure was achieved 16 weeks after the first treatment dose for both regimens. Following the weekly administration of 0.4 mg/kg, the mean Cmax (coefficient of variation, CV%) was 2940 ng/mL (67%), respectively. Following the biweekly administration of 0.8 mg/kg, the Cmax (CV%) was 3410 ng/mL (63%), respectively.L47765 The geometric mean (coefficient of variation CV %) bioavailability of talquetamab was 59% (22%) when administered subcutaneously. The median (range) Tmax of talquetamab after the first and 17th treatment dose of 0.4 mg/kg weekly were 3.7 (0.9 to 7) days and 2.5 (0.9 to 5.9) days, respectively. The median (range) Tmax of talquetamab after the first and 9th treatment dose of 0.8 mg/kg every two weeks were 3.4 (0.8 to 14) days and 3.6 (1 to 7.7) days, respectively.L47765

Metabolisme

Talquetamab is expected to be metabolized into small peptides by catabolic pathways.L47765

Rute Eliminasi

No information is available.

Interaksi Obat

38 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talquetamab.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Talquetamab.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Talquetamab.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Talquetamab.
Lidocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Tetrodotoxin.
Ambroxol The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Ambroxol.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Talquetamab is combined with Quinisocaine.
Etrasimod The risk or severity of immunosuppression can be increased when Talquetamab is combined with Etrasimod.

Target Protein

T-cell surface glycoprotein CD3 CD3D
G-protein coupled receptor family C group 5 member D GPRC5D

Referensi & Sumber

Artikel (PubMed)
  • PMID: 32040549
    Pillarisetti K, Edavettal S, Mendonca M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, Gaudet F: A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243. doi: 10.1182/blood.2019003342.
  • PMID: 33890981
    Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ: Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Talvey
    Injection • 3 mg/1.5mL • Subcutaneous • US • Approved
  • Talvey
    Injection • 40 mg/1mL • Subcutaneous • US • Approved
  • Talvey
    Solution • 2 mg / mL • Subcutaneous • Canada • Approved
  • Talvey
    Solution • 40 mg / mL • Subcutaneous • Canada • Approved
  • Talvey
    Injection, solution • 2 mg/ml • Subcutaneous • EU • Approved
  • Talvey
    Injection, solution • 40 mg/ml • Subcutaneous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul